RJA
SLRN

Raymond James & Associates’s ACELYRIN SLRN Stock Holding History

Raymond James & Associates’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,364
Closed -$76.7K – 4075
2024
Q1 		$76.7K Buy
11,364
+842
+8% +$6.4K ﹤0.01% 3762
2023
Q4 		$78.5K Sell
10,522
-8,034
-43% -$68.6K ﹤0.01% 3668
2023
Q3 		$189K Buy
+18,556
New +$394K ﹤0.01% 3476

Other funds holding SLRN

ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Raymond James & Associates's SLRN Position: Q2 2024 in Review

Raymond James & Associates sold out of ACELYRIN (SLRN) in Q2 2024, closing a stake of 11,364 shares — an estimated $76.7K sold.

Raymond James & Associates first reported a position in SLRN in Q3 2023 and held it in 3 quarters. The position peaked at $189K in Q3 2023. 112 funds tracked by Wall St. Rank hold SLRN as of Q2 2024.

  • Raymond James & Associates reported no remaining ACELYRIN position as of Q2 2024 after selling out during the quarter.
  • Raymond James & Associates sold 11,364 ACELYRIN shares in Q2 2024, an estimated $76.7K.
  • Raymond James & Associates first reported a position in ACELYRIN in Q3 2023 and held it in 3 quarters.
  • Raymond James & Associates's ACELYRIN position peaked at $189K in Q3 2023.
  • 112 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2024.

Based on Raymond James & Associates's 13F filing for Q2 2024, filed 19 Jul 2024.